XM does not provide services to residents of the United States of America.

DaVita lifts annual profit forecast on strong kidney dialysis services demand



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>DaVita lifts annual profit forecast on strong kidney dialysis services demand</title></head><body>

Aug 6 (Reuters) -Healthcare company DaVita DVA.N raised its 2024 profit forecast on Tuesday expecting strong demand for its kidney dialysis services, sending shares of the company up 3% in aftermarket trade.

Shares of DaVita, similar to those of its peers, witnessed a steep fall in October last year and gradually recovered in 2024, after the company downplayed speculations over the impact of new GLP-1 weight-loss drugs potentially dampening the market for dialysis services.

The Colorado-based firm now sees 2024 adjusted per-share profit between $9.25 and $10.05, raised from its previous view of $9.00 and $9.80.

Analysts' average estimate for annual per share profit is pegged at $9.32, according to LSEG data.

The company provides care servicesin the United States to patients suffering from chronic kidney failure through a network of outpatient clinics and at-home dialysis services.

DaVita said it continued to experience delays in claims processing through the first half of 2024 as a result of the Change Healthcare outage, for which it applied for and received interest-free funding from UnitedHealth UNH.N.

The company posted quarterly revenue of $3.19billion, ahead of analysts' estimate of $3.15billion.

On an adjusted basis, it reported a profit of $2.59per share for the quarter, above analysts' estimate of $2.54per share.





Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.